Roche Holding AG (SWX:ROG)

Switzerland · Delayed Price · Currency is CHF

259.90

+0.70 (0.27%)

May 23, 2025, 5:30 PM CET

Roche Holding AG Employees

Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.

Employees

103,249

Change (1Y)

-356

Growth (1Y)

-0.34%

Revenue / Employee

604.32K CHF

Profits / Employee

80.17K CHF

Market Cap

208.55B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	103,249	-356	-0.34%
Dec 31, 2023	103,605	-8	-0.01%
Dec 31, 2022	103,613	2,693	2.67%
Dec 31, 2021	100,920	-545	-0.54%
Dec 31, 2020	101,465	3,730	3.82%
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro
Dec 31, 2016	Pro	Pro	Pro
Dec 31, 2015	Pro	Pro	Pro

Related Stocks

Company Name	Employees
Novartis AG	75,883
Lonza Group AG	18,944
Alcon	25,599
Galderma Group AG	6,545
Sandoz Group AG	22,049
Straumann Holding AG	11,815
Sonova Holding AG	18,366
Ypsomed Holding AG	2,296

Employee Rankings

Roche Holding AG News

1 day ago - Tandem to pay Roche $36M in patent dispute settlement - Seeking Alpha
1 day ago - Roche wins EU endorsement for metastatic breast cancer treatment - Seeking Alpha
2 days ago - CHMP recommends EU approval of Roche's Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer - GlobeNewsWire
2 days ago - Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology - GlobeNewsWire
2 days ago - New two-year follow-up of Roche's Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients - GlobeNewsWire
2 days ago - New Two-year Follow-up of Genentech's Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients - Business Wire
2 days ago - Roche’s Susvimo approved by FDA for diabetic retinopathy - Seeking Alpha
2 days ago - FDA Approves Genentech's Susvimo for Diabetic Retinopathy - Business Wire